Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

B7-H3 CAR-T for Recurrent or Refractory Glioblastoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04077866
Recruitment Status : Not yet recruiting
First Posted : September 4, 2019
Last Update Posted : September 4, 2019
Ningbo Yinzhou People's Hospital
Huzhou Central Hospital
BoYuan RunSheng Pharma (Hangzhou) Co., Ltd.
Information provided by (Responsible Party):
Second Affiliated Hospital, School of Medicine, Zhejiang University

No Study Results Posted on for this Study
Recruitment Status : Not yet recruiting
Estimated Primary Completion Date : May 1, 2024
Estimated Study Completion Date : May 1, 2024